Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin

This study is currently recruiting participants.

Verified March 2013 by Sanofi

Sponsor:

Information provided by (Responsible Party):

Sanofi

ClinicalTrials.gov Identifier:

NCT01079039

First received: February 27, 2010

Last updated: March 21, 2013

Last verified: March 2013

History of Changes

Purpose

The purpose of this study is to determine during the course of 5 years, the patterns of pertussis vaccine usage by brand and dose among children birth through 59 months of age who have received no more than four doses of pertussis vaccine, residing in the state of Wisconsin.

The state of Wisconsin conducts comprehensive surveillance for pertussis disease. Data from this brand exposure survey will be used to determine brand-specific rates of pertussis disease among Wisconsin residents birth through 59 months of age.

Condition	Phase
Pertussis	Phase 4

Study Type:	Observational
Study Design:	Observational Model: Cohort
Official Title:	Survey for Usage Rates of Pertussis Vaccines by Brand Among Persons Birth Through 59 Months of Age in the State of Wisconsin

Resource links provided by NLM:

MedlinePlus related topics: Whooping Cough

U.S. FDA Resources

Further study details as provided by Sanofi:

Primary Outcome Measures:

Receipt of any pertussis vaccine confirmed by survey methods [ Time Frame: 5 Years ] [ Designated as safety issue: No ]

Estimated Enrollment:	12000
Study Start Date:	February 2010
Estimated Study Completion Date:	June 2015
Estimated Primary Completion Date:	February 2015 (Final data collection date for primary outcome measure)

Groups/Cohorts
Pertussis vaccine users Participants who have received no more than four doses of pertussis vaccine and residing in the state of Wisconsin.

Detailed Description:

This study supports the fulfillment of a post-licensure commitment to monitor vaccine-specific rates of pertussis breakthrough disease among children given Pentacel vaccine or other pertussis vaccines.

Ongoing telephone sample surveys will (with parental consent) collect brand-specific pertussis vaccine/dosing information from health care providers of children living in the catchment area.

These brand exposure data will be used, along with pertussis surveillance data, to satisfy an FDA commitment to calculate brand-specific rates of pertussis disease during the study period among persons birth through 59 months of age residing in Wisconsin.

No vaccines will be provided or administered for this study.

Eligibility

Ages Eligible for Study:	2 Months to 59 Months
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Participants who have received no more than four doses of pertussis vaccine and residing in the state of Wisconsin.

Criteria

Inclusion Criteria :

Persons will be eligible for inclusion in the survey population for this brand usage study whenever the following three conditions are true: the individual resides in Wisconsin, is age 2 through 59 months, and the date is within the 5-year survey period

Exclusion Criteria :

Not applicable.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01079039

Contacts

Contact: Public Registry Sanofi Pasteur

RegistryContactUs@sanofipasteur.com

Locations

United States, Wisconsin
	Recruiting
Appleton, Wisconsin, United States
	Recruiting
Bear Creek, Wisconsin, United States
	Recruiting
Eau Claire, Wisconsin, United States
	Recruiting
Fairchild, Wisconsin, United States
	Recruiting
Grand Rapids, Wisconsin, United States
	Recruiting
Green Bay, Wisconsin, United States
	Recruiting
Greenfield, Wisconsin, United States
	Recruiting
Janesville, Wisconsin, United States
	Recruiting
Kenosha, Wisconsin, United States
	Recruiting
Madison, Wisconsin, United States
	Recruiting
Maple Bluff, Wisconsin, United States
	Recruiting
Milton, Wisconsin, United States
	Recruiting
Milwaukee, Wisconsin, United States
	Recruiting
Oshkosh, Wisconsin, United States
	Recruiting
Racine, Wisconsin, United States
	Recruiting
Rochester, Wisconsin, United States
	Recruiting
Twin Lakes, Wisconsin, United States
	Recruiting
Waukesha, Wisconsin, United States
	Recruiting
Willow Springs, Wisconsin, United States
	Recruiting
Winnebago, Wisconsin, United States

Sponsors and Collaborators

Sanofi

Investigators

Study Director:

Medical Director

Sanofi Pasteur Inc.

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Sanofi
ClinicalTrials.gov Identifier:	NCT01079039 History of Changes
Other Study ID Numbers:	M5A17, UTN: U1111-1112-2615
Study First Received:	February 27, 2010
Last Updated:	March 21, 2013
Health Authority:	United States: Food and Drug Administration

Keywords provided by Sanofi:

Pertussis
Pertussis vaccine

Additional relevant MeSH terms:

Whooping Cough
Bordetella Infections
Gram-Negative Bacterial Infections
Bacterial Infections

Respiratory Tract Infections
Infection
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 16, 2013

To Top